LifeStance Health Group Inc. reported a net loss of $3.8 million, a significant improvement from the net loss of $23.3 million in the previous period. In the second quarter, the company achieved net cash provided by operations amounting to $64.4 million and a free cash flow of positive $56.6 million. Adjusted EBITDA increased by 19%, reaching $34.0 million, compared to $28.6 million previously. For the full year 2025, LifeStance reiterated its revenue expectations of $1.40 billion to $1.44 billion. The company raised its Center Margin expectations to $441 million to $465 million and increased its Adjusted EBITDA expectations to a range of $140 million to $150 million. CEO Dave Bourdon highlighted the addition of over 170 clinicians and improved productivity, contributing to double-digit organic revenue growth and 10% Adjusted EBITDA margins.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.